Veterinary and comparative oncology最新文献

SHINE - Validation of Near Infrared Fluorescence Lymphography Against Lymphoscintigraphy for Sentinel Lymph Node Biopsy in Dogs With Mast Cell Tumours. 近红外荧光淋巴显像对肥大细胞肿瘤犬前哨淋巴结活检的有效性验证。

IF 2.3 2区农林科学

Veterinary and comparative oncology Pub Date : 2025-06-01 Epub Date: 2025-04-11 DOI: 10.1111/vco.13058

L E Chiti, P Beer, S M Ohlerth, S Hartnack, M C Nolff

{"title":"SHINE - Validation of Near Infrared Fluorescence Lymphography Against Lymphoscintigraphy for Sentinel Lymph Node Biopsy in Dogs With Mast Cell Tumours.","authors":"L E Chiti, P Beer, S M Ohlerth, S Hartnack, M C Nolff","doi":"10.1111/vco.13058","DOIUrl":"10.1111/vco.13058","url":null,"abstract":"Lymphoscintigraphy is the gold standard among sentinel lymph node (SLN) mapping techniques. Unfortunately, lymphoscintigraphy is not readily accessible, leading to the need for validation of alternative techniques. The aim of this study is to compare near-infrared fluorescence lymphography (NIRF-L) with lymphoscintigraphy for SLN resection in MCT and assess the impact of intraoperative NIRF guidance. Forty-eight dogs with 60 MCT were included in this prospective, blinded, randomised controlled trial. Dogs underwent preoperative lymphoscintigraphy and were then randomised into two groups: in the treatment group (n = 30) intraoperative NIRF-L was performed; in the control group (n = 30) no intraoperative guidance was implemented. Detection rate, concordance, sensitivity, and negative predictive values were recorded for NIRF-L and lymphoscintigraphy. Surgical time and length of surgical incision were compared between treatment and control groups with the Wilcoxon test (5% significance). Detection rate was 100% for NIRF-L and 98% for lymphoscintigraphy. Discordance occurred in one case. Sensitivity of NIRF-L was 93.7% (95% C.I. 74.3%-99.3%) and negative predictive value ranged between 91.1% and 98.6% with a prevalence of nodal metastases of 61% and 18%. Based on the overlapping of the confidence intervals, NIRF-L was not statistically different to lymphoscintigraphy for sensitivity. Lymphadenectomy was unsuccessful in 4/30 (13%) cases in the control group. Surgical time and incision were significantly shorter in the treatment group (p < 0.001; p = 0.001). Based on our results, NIRF-L is a valid alternative to lymphoscintigraphy for SLN removal in MCT. Moreover, it improves the success of lymphadenectomy, reduces surgical time, and incision length compared to an unguided technique.","PeriodicalId":23693,"journal":{"name":"Veterinary and comparative oncology","volume":" ","pages":"320-329"},"PeriodicalIF":2.3,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144018023","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"农林科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Adjuvant Chemotherapy Is Associated With Prolonged Survival Time in Small-Breed Dogs Undergoing Amputation for Appendicular Osteosarcoma. 辅助化疗与因阑尾骨肉瘤而截肢的小型犬的生存时间延长有关。

IF 2.3 2区农林科学

Veterinary and comparative oncology Pub Date : 2025-06-01 Epub Date: 2025-01-11 DOI: 10.1111/vco.13041

Stefano Zanardi, Silvia Sabattini, Federica Rossi, Matteo Rossanese, Paolo Buracco, Vincenzo Montinaro, Marina Aralla, Alfredo Dentini, Elisa Pizzi, Enrico Volpe, Giovanni Tremolada, Laura Marconato

{"title":"Adjuvant Chemotherapy Is Associated With Prolonged Survival Time in Small-Breed Dogs Undergoing Amputation for Appendicular Osteosarcoma.","authors":"Stefano Zanardi, Silvia Sabattini, Federica Rossi, Matteo Rossanese, Paolo Buracco, Vincenzo Montinaro, Marina Aralla, Alfredo Dentini, Elisa Pizzi, Enrico Volpe, Giovanni Tremolada, Laura Marconato","doi":"10.1111/vco.13041","DOIUrl":"10.1111/vco.13041","url":null,"abstract":"Adjuvant chemotherapy is a well-established treatment for large-breed dogs with appendicular osteosarcoma; however, it is unclear if it improves outcomes in small-breed dogs due to limited focused studies. This retrospective study aimed to investigate the oncologic outcomes of dogs weighting less than 15 kg with appendicular osteosarcoma that underwent curative resection with or without postoperative adjuvant chemotherapy. Endpoints were time to distant progression (TTDP) and overall survival (OS). Medical records from multiple institutions were reviewed, and 43 dogs were included in the analysis: 17 underwent surgery alone and 26 also received adjuvant chemotherapy. The median TTDP for all dogs was 265 days, with no significant difference between treatment groups. The median OS for all dogs was 270 days, and it was significantly different between amputated dogs (150 days) and those also receiving adjuvant chemotherapy (353 days, p = 0.002). In our cohort, osteosarcoma in small breeds behaved as aggressive as in large breeds. Adjuvant chemotherapy may prolong survival. Future randomised studies are needed to provide definitive evidence on the necessity of adjuvant chemotherapy to address metastatic spread in small-breed dogs with appendicular osteosarcoma.","PeriodicalId":23693,"journal":{"name":"Veterinary and comparative oncology","volume":" ","pages":"161-167"},"PeriodicalIF":2.3,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12082752/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142967004","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"农林科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Retrospective Study Evaluating the Outcome and Efficacy of Stereotactic Body Radiation Therapy for the Treatment of Metastatic Abdominal Lymph Nodes in Dogs With Apocrine Gland Anal Sac Adenocarcinoma. 立体定向放射治疗犬大汗腺肛囊腺癌转移性腹部淋巴结的疗效及预后的回顾性研究。

IF 2.3 2区农林科学

Veterinary and comparative oncology Pub Date : 2025-06-01 Epub Date: 2025-03-20 DOI: 10.1111/vco.13052

Tiffany W Martin, Theodore Chang, Mary-Keara Boss, Brandan Janssens, Susan M LaRue

{"title":"Retrospective Study Evaluating the Outcome and Efficacy of Stereotactic Body Radiation Therapy for the Treatment of Metastatic Abdominal Lymph Nodes in Dogs With Apocrine Gland Anal Sac Adenocarcinoma.","authors":"Tiffany W Martin, Theodore Chang, Mary-Keara Boss, Brandan Janssens, Susan M LaRue","doi":"10.1111/vco.13052","DOIUrl":"10.1111/vco.13052","url":null,"abstract":"Local treatment for dogs with regional lymph node metastasis secondary to apocrine gland anal sac adenocarcinoma (AGASACA) includes nodal extirpation or radiotherapy. Stereotactic body radiation therapy (SBRT) may provide a definitive intent treatment option for macroscopic nodal disease when surgery is declined or the disease is deemed inoperable. Twenty-five dogs receiving SBRT to the metastatic sacroiliac lymph nodes were retrospectively evaluated. Dogs were staged according to the previously published TNM staging system with 3 stage IIIa, 14 stage 3b, and 8 stage IV. The overall median survival time (MST) was 451 days and the stage did not significantly impact survival (p = 0.31). The overall median event-free survival time was 246 days. Significant positive prognostic factors included male sex, higher dose per fraction, and higher total dose (p = 0.034, 0.0035, 0.0047). Dogs receiving 6-7.5 Gy per fraction with a total dose of 30-37.5 Gy outperformed dogs receiving other protocols. Twelve dogs experienced gait changes in the hind limbs during the late radiation effects period. Resolution of hypercalcemia in 5 dogs was inconsistent and transient. The best response was complete in 21%, partial in 58%, and stable disease in 17% at a median of 100 days. Three dogs (12%) developed progression of treated lymph nodes at 157, 498, and 644 day. Eight dogs (32%) had recurrence of their primary (untreated by radiation) anal sac masses. SBRT was determined to be an effective alternative to surgical excision; however, more investigation is needed to determine the cause of gait changes in the late toxicity period.","PeriodicalId":23693,"journal":{"name":"Veterinary and comparative oncology","volume":" ","pages":"257-266"},"PeriodicalIF":2.3,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143664585","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"农林科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Genotoxic Herbicide Exposures in Golden Retrievers With and Without Multicentric Lymphoma. 患有和未患有多中心淋巴瘤的金毛寻回犬暴露于遗传毒性除草剂的情况。

IF 2.3 2区农林科学

Veterinary and comparative oncology Pub Date : 2025-06-01 Epub Date: 2025-03-21 DOI: 10.1111/vco.13051

Ashleigh N Tindle, Lauren M Krueger, Brenna Swafford, Erin Mani, Camille Danielson, Julia Labadie, Lauren A Trepanier

{"title":"Genotoxic Herbicide Exposures in Golden Retrievers With and Without Multicentric Lymphoma.","authors":"Ashleigh N Tindle, Lauren M Krueger, Brenna Swafford, Erin Mani, Camille Danielson, Julia Labadie, Lauren A Trepanier","doi":"10.1111/vco.13051","DOIUrl":"10.1111/vco.13051","url":null,"abstract":"Canine multicentric lymphoma (CML) is one of the most common malignancies in dogs. Although breed risk is important, environmental factors such as herbicides have also been implicated. The objective of this study was to determine whether genotoxic exposures to the herbicides 2,4-D and glyphosate are associated with CML, using dogs from the Golden Retriever Lifetime Study cohort. We measured urinary concentrations of glyphosate and 2,4-D in golden retrievers with CML and matched unaffected controls at two time points: at the time of diagnosis and 1 year prior to diagnosis. To assess the genotoxic potential of herbicide exposures, we used reverse dosimetry from urinary concentrations to estimate plasma concentrations. We then assessed the genotoxicity of these herbicide concentrations towards healthy canine peripheral blood mononuclear cells (PBMC's) in vitro using the CometChip assay, with and without canine liver microsomes. All dogs had detectable urinary exposures to 2,4-D (7.3-42.9 ng/mg creat) and glyphosate (0.4-80.7 ng/mg creat), with no differences between cases and controls at either time point. Both 2,4-D and glyphosate were genotoxic to canine PBMCs at concentrations of 0.10 μM and higher, with no consistent effects of canine liver microsomes on herbicide genotoxicity. No dogs reached estimated genotoxic plasma concentrations for glyphosate, but 4 of 30 golden retrievers with CML (13.3%) and 2 of 30 control dogs (6.7%) reached estimated genotoxic 2,4-D exposures (p = 0.67).","PeriodicalId":23693,"journal":{"name":"Veterinary and comparative oncology","volume":" ","pages":"246-256"},"PeriodicalIF":2.3,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12082782/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143671086","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"农林科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Tolerability Assessment of Orally Administered Paclitaxel With Encequidar in Dogs With Spontaneous Malignancy. 口服紫杉醇联合恩奎达治疗犬自发性恶性肿瘤的耐受性评价。

IF 2.3 2区农林科学

Veterinary and comparative oncology Pub Date : 2025-06-01 Epub Date: 2025-02-26 DOI: 10.1111/vco.13045

Jordan Ziegler, Jacob Cawley, Stephanie Istvan, Saya Press, Samuel Stewart, Chand Khanna, Joelle Fenger

{"title":"Tolerability Assessment of Orally Administered Paclitaxel With Encequidar in Dogs With Spontaneous Malignancy.","authors":"Jordan Ziegler, Jacob Cawley, Stephanie Istvan, Saya Press, Samuel Stewart, Chand Khanna, Joelle Fenger","doi":"10.1111/vco.13045","DOIUrl":"10.1111/vco.13045","url":null,"abstract":"Paclitaxel is an antimitotic agent that targets elements of the cancer phenotype, including cell proliferation, DNA repair, and apoptosis, predicting its broad activity in a spectrum of cancers. An oral paclitaxel formulation has been developed to overcome challenges associated with parenteral administration of this drug, notably the development of Cremophor-induced acute hypersensitivity reactions, which are particularly problematic in dogs. The aim of this open-label, dose-escalating study was to evaluate the tolerability and determine the maximum tolerated dosage (MTD) and dose-limiting toxicity (DLT) of oral paclitaxel when co-administered with the P-glycoprotein pump inhibitor, encequidar, in dogs with cancer. Paclitaxel was administered as a 3-consecutive-day course starting at 90 mg/m2 with encequidar weekly for 3 weeks, using escalation of 30 mg/m2 increments. MTD was established using a rolling-six dose escalation study design, based on the number of dogs experiencing any DLT assessed after each dosing cycle and during a 28-day post-treatment monitoring period. Nineteen client-owned dogs were enrolled. MTD was established at 90 mg/m2 and the most frequent adverse events (AEs) were gastrointestinal, followed by hematologic, with the majority being self-resolving and low grade. VCOG Grades 3 and 4 gastrointestinal toxicity, Grade 4 neutropenia, and acute kidney injury were defined as DLTs at 120 mg/m2. Conclusions of this study define oral paclitaxel MTD in cancer-bearing dogs at 90 mg/m2 when given with encequidar for 3 consecutive days weekly for 3 weeks. Future Phase 2 trials evaluating the therapeutic activity of oral paclitaxel at its MTD co-administered with encequidar in defined tumour histologies are warranted.","PeriodicalId":23693,"journal":{"name":"Veterinary and comparative oncology","volume":" ","pages":"197-204"},"PeriodicalIF":2.3,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143516856","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"农林科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Half-Body Radiation Therapy Results in a Prolonged Progression-Free Interval in Canine High-Grade Lymphoma After First Remission. 犬高级别淋巴瘤首次缓解后半体放射治疗导致无进展时间延长。

IF 2.3 2区农林科学

Veterinary and comparative oncology Pub Date : 2025-06-01 Epub Date: 2025-03-15 DOI: 10.1111/vco.13050

Yen-Hao Erik Lai, Sarah Lyles, Mark Mitchell, Jayme Looper

{"title":"Half-Body Radiation Therapy Results in a Prolonged Progression-Free Interval in Canine High-Grade Lymphoma After First Remission.","authors":"Yen-Hao Erik Lai, Sarah Lyles, Mark Mitchell, Jayme Looper","doi":"10.1111/vco.13050","DOIUrl":"10.1111/vco.13050","url":null,"abstract":"An optimal protocol of adding wide-field irradiation to multi-agent chemotherapy for dogs with lymphoma has not been established. The aim of this retrospective case-control study was to evaluate the efficacy of a protocol combining chemotherapy and half-body irradiation (HBI) for dogs with high-grade lymphoma. Dogs in the treatment group received cranial HBI 2 weeks after completing the second cycle of the multi-agent chemotherapy protocol. The radiation therapy protocol consisted of 4 Gy/fraction once per day for 2 consecutive days for the cranial half body, followed by the same protocol for the caudal half 2 weeks later. The control group only received multi-agent chemotherapy. All patients were required to have cytological confirmation of high-grade lymphoma and achieve complete remission after two cycles of multi-agent chemotherapy. Fourteen patients receiving HBI and 11 patients in the control group were included. The median progression-free interval (PFI) in the HBI group (1143 days) was significantly longer than that in the control group (316 days, p = 0.004). In the HBI group, dogs with T cell lymphoma had statistically shorter PFI (292 days) than dogs with B cell lymphoma (2127 days, p = 0.0013). The median survival time in the HBI group (1924 days) was significantly longer than that in the chemotherapy-only group (566 days, p = 0.0077). The predictive factors for longer PFI and ST were found in the patients who received HBI and chemotherapy (p = 0.0062 and 0.0252, respectively). For chemotherapy-responding patients that completed a multi-agent protocol, HBI significantly prolonged the time to tumour relapse compared with the chemotherapy-only group.","PeriodicalId":23693,"journal":{"name":"Veterinary and comparative oncology","volume":" ","pages":"236-245"},"PeriodicalIF":2.3,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12082781/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143634701","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"农林科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Prognostic Implications of Decorin, E-Cadherin and EGFR Expression in Inflammatory and Non-Inflammatory Canine Mammary Carcinomas. 炎性和非炎性犬乳腺癌中Decorin， E-Cadherin和EGFR表达的预后意义。

IF 2.3 2区农林科学

Veterinary and comparative oncology Pub Date : 2025-06-01 Epub Date: 2025-01-23 DOI: 10.1111/vco.13042

Bethânia Almeida Gouveia, Fernanda Ramalho Ramos, Ingrid Kester Lima Silva, Thalita Evani Silva de Oliveira, Rosemeri de Oliveira Vasconcelos, José Guilherme Xavier, Ricardo Francisco Strefezzi

{"title":"Prognostic Implications of Decorin, E-Cadherin and EGFR Expression in Inflammatory and Non-Inflammatory Canine Mammary Carcinomas.","authors":"Bethânia Almeida Gouveia, Fernanda Ramalho Ramos, Ingrid Kester Lima Silva, Thalita Evani Silva de Oliveira, Rosemeri de Oliveira Vasconcelos, José Guilherme Xavier, Ricardo Francisco Strefezzi","doi":"10.1111/vco.13042","DOIUrl":"10.1111/vco.13042","url":null,"abstract":"Inflammatory mammary carcinoma (IMC) is the most aggressive variant of invasive mammary tumours in dogs and in women. Decorin is an extracellular matrix molecule whose expression can be reduced or absent in various human cancers, which is associated with a poor prognosis. E-cadherin is a cell adhesion protein whose expression is reduced in several neoplasms. However, it is overexpressed in inflammatory breast cancers of women. EGFR is also associated with cancer development and is commonly overexpressed in aggressive neoplasms. This study aimed to characterise the expressions of Decorin, E-cadherin, and EGFR in canine inflammatory and non-inflammatory mammary carcinomas (IMC and non-IMC) and to evaluate their expression levels as prognostic indicators for survival and occurrence of metastases. Thirty-three IMC and 43 non-IMC cases were analysed retrospectively and submitted to immunohistochemical analysis. The reactions were quantified in five high-power field images from areas of the highest intensity and frequency of immunostaining (hot spots). We found significantly lower expression of Decorin and higher of E-cadherin and EGFR in canine IMCs. Patients with tumours that exhibited Decorin expression in less than 26.35% of epithelial cells had shorter survival (p = 0.0410) and a higher occurrence of distant metastases (p = 0.0115). E-cadherin is overexpressed in canine IMCs (p < 0.0001), similar to what occurs in women, reinforcing that dogs can be used as a study model for human IMC. EGFR overexpression in canine IMCs (p = 0.0322) provides evidence for potential targeted therapy with tyrosine kinase inhibitors.","PeriodicalId":23693,"journal":{"name":"Veterinary and comparative oncology","volume":" ","pages":"168-177"},"PeriodicalIF":2.3,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143034299","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"农林科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Clinical Guidelines for Canine Transmissible Venereal Tumour Treatment: Systematic Review and Meta-Analysis. 犬传染性性病肿瘤治疗临床指南：系统回顾和荟萃分析。

IF 2.3 2区农林科学

Veterinary and comparative oncology Pub Date : 2025-06-01 Epub Date: 2025-01-13 DOI: 10.1111/vco.13038

Pedro Antônio Bronhara Pimentel, Antonio Giuliano, Petros Odatzoglou, Natalia Ignatenko, Raphael Rocha Wenceslau, Isabella Oliveira Almeida, Paloma Helena Sanches da Silva, Mariana de Pádua Costa, Rodrigo Dos Santos Horta

{"title":"Clinical Guidelines for Canine Transmissible Venereal Tumour Treatment: Systematic Review and Meta-Analysis.","authors":"Pedro Antônio Bronhara Pimentel, Antonio Giuliano, Petros Odatzoglou, Natalia Ignatenko, Raphael Rocha Wenceslau, Isabella Oliveira Almeida, Paloma Helena Sanches da Silva, Mariana de Pádua Costa, Rodrigo Dos Santos Horta","doi":"10.1111/vco.13038","DOIUrl":"10.1111/vco.13038","url":null,"abstract":"The treatment of canine transmissible venereal tumour (CTVT) has evolved since its initial description in 1810. Initially considered untreatable in the early 20th century, extensive research over time has significantly advanced our understanding of its aetiopathogenesis. This led to successful chemotherapy treatments, which have shown superior outcomes compared to surgical interventions. Vincristine, in particular, has proven effective in treating CTVT. However, the development of chemoresistance underscores the need to explore alternative therapeutic options. This systematic review provides a comprehensive analysis of CTVT treatment practices from 1950 to 2023, aiming to establish a gold standard and enhance clinical decision-making. Initially, 3633 studies were identified, with 42 meeting the eligibility criteria. Our findings suggest that vincristine sulphate monotherapy is the recommended first-line treatment for CTVT. Administering vincristine intravenously at a dosage of 0.5-0.75 mg/m2 weekly for 4-6 sessions resulted in a 93.1% (67.4%-100%) complete response rate in dogs. Extending the treatment to eight sessions increased the complete response rate to 98.9% (83.3%-100%). Radiation therapy, lomustine and doxorubicin are viable second-line treatment options; however, extensive cohort studies are required to confirm their efficacy in achieving remission in vincristine-resistant cases. Additionally, no clear criteria could be established for initiating treatment with drugs other than vincristine in previously untreated dogs. Surgery is considered a third-line option. Notably, complete remission is anticipated following recommended systemic and local therapies in nearly all cases. Despite concerns about chemoresistance, current guidelines indicate a favourable response to suggested treatments even in resistant cases.","PeriodicalId":23693,"journal":{"name":"Veterinary and comparative oncology","volume":" ","pages":"125-140"},"PeriodicalIF":2.3,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142980107","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"农林科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Early-Delayed Radiotoxicity Associated With Stereotactic Radiation Therapy Following a Daily 6 Gy × 5 (30 Gy) Protocol for Presumed Canine Intracranial Meningiomas. 犬颅内脑膜瘤的早期迟发性放射毒性与每日6 Gy × 5 （30 Gy）立体定向放射治疗相关。

IF 2.3 2区农林科学

Veterinary and comparative oncology Pub Date : 2025-06-01 Epub Date: 2025-01-19 DOI: 10.1111/vco.13040

James Elliott

{"title":"Early-Delayed Radiotoxicity Associated With Stereotactic Radiation Therapy Following a Daily 6 Gy × 5 (30 Gy) Protocol for Presumed Canine Intracranial Meningiomas.","authors":"James Elliott","doi":"10.1111/vco.13040","DOIUrl":"10.1111/vco.13040","url":null,"abstract":"Early-delayed side effects (EDSEs) following treatment of canine intracranial meningiomas with 1-3-fraction stereotactic radiation therapy (SRT) can cause worsening neurologic signs, and one potential method of mitigating this toxicity is reducing the dose per fraction. Twenty dogs with imaging-diagnosed intracranial meningiomas and telephone follow-up of at least 6 months received a protocol of 6 Gy × 5, daily (30 Gy). A 'possible EDSE' was defined as mental dullness, neurologic exacerbation of existing neurologic signs or new neurologic signs occurring within 1-4 months of completing SRT, regardless of the response to steroids and even if an MRI was not performed. A 'probable EDSE' was defined as mental dullness, neurologic exacerbation of existing neurologic signs or new neurologic signs occurring within 1-4 months of completing SRT. These signs were either reversible with the initiation or increased doses of prednisolone, or follow-up MRI revealed no evidence of an alternate explanation. No dogs experienced acute radiotoxicity or clinical signs compatible with EDSEs. The protocol appears to result in limited acute radiotoxicity, and further evaluation of the frequency of long-term toxicities and relative efficacy should be undertaken.","PeriodicalId":23693,"journal":{"name":"Veterinary and comparative oncology","volume":" ","pages":"152-160"},"PeriodicalIF":2.3,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143012699","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"农林科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Knockdown of Methylenetetrahydrofolate Dehydrogenase/Cyclohydrolase 2 Promotes an Epithelial-Like Phenotype in Canine Mammary Carcinoma Cells. 亚甲基四氢叶酸脱氢酶/环水解酶2的下调促进了犬乳腺癌细胞的上皮样表型

IF 2.3 2区农林科学

Veterinary and comparative oncology Pub Date : 2025-06-01 Epub Date: 2025-04-13 DOI: 10.1111/vco.13055

Yukino Machida, Remika Onagi, Kazuhiko Ochiai, Tatsunori Nishimura, Tomokazu Nagashima, Takayuki Nakagawa, Noriko Gotoh, Masaki Michishita

{"title":"Knockdown of Methylenetetrahydrofolate Dehydrogenase/Cyclohydrolase 2 Promotes an Epithelial-Like Phenotype in Canine Mammary Carcinoma Cells.","authors":"Yukino Machida, Remika Onagi, Kazuhiko Ochiai, Tatsunori Nishimura, Tomokazu Nagashima, Takayuki Nakagawa, Noriko Gotoh, Masaki Michishita","doi":"10.1111/vco.13055","DOIUrl":"10.1111/vco.13055","url":null,"abstract":"In cancer cells, folate is metabolised in the cytoplasm and mitochondria. Folate metabolism mediates nucleic acid synthesis and, thereby, the growth of cancer cells. One of the enzymes within this folate metabolic pathway, methylenetetrahydrofolate dehydrogenase/cyclohydrolase 2 (MTHFD2), is rarely expressed in normal adult cells but is abundantly expressed in the mitochondria and nuclei of foetal and cancer cells in humans and mice. In this study, we examined the localisation and function of MTHFD2 in canine mammary cancer cells. MTHFD2 was expressed in the nuclei and mitochondria of canine mammary carcinoma cell lines. Short-term inhibition of MTHFD2 with an inhibitor reduced the growth of each cell line. Furthermore, long-term decreased expression, mimicked by the knockdown of MTHFD2 by RNA interference, resulted in epithelial-like cell morphology and reduced migratory ability without inducing apoptosis. Increased expression of the epithelial marker E-cadherin in MTHFD2-knock down cells suggested an enhanced epithelial-like phenotype through the inhibition of MTHFD2. To our knowledge, this is the first study to analyse the function of MTHFD2 in canine mammary carcinomas.","PeriodicalId":23693,"journal":{"name":"Veterinary and comparative oncology","volume":" ","pages":"290-299"},"PeriodicalIF":2.3,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144016559","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"农林科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0